par Vinci, Chiara 
;Infantino, M;Raturi, S;Tindell, A;Topping, L M;Strollo, Rocky;Amital, H;Shoenfeld, Yehuda;Gertel, S;Grossi, V;Manfredi, M;Rutigliano, I M;Bandinelli, F;Li Gobbi, F;Damiani, A.;Pozzilli, Paolo;Mcinnes, I B;Goodyear, C S;Benucci, M;Nissim, A
Référence Scandinavian journal of rheumatology, 49, 4, page (281-291)
Publication Publié, 2020-07-01
;Infantino, M;Raturi, S;Tindell, A;Topping, L M;Strollo, Rocky;Amital, H;Shoenfeld, Yehuda;Gertel, S;Grossi, V;Manfredi, M;Rutigliano, I M;Bandinelli, F;Li Gobbi, F;Damiani, A.;Pozzilli, Paolo;Mcinnes, I B;Goodyear, C S;Benucci, M;Nissim, ARéférence Scandinavian journal of rheumatology, 49, 4, page (281-291)
Publication Publié, 2020-07-01
Article révisé par les pairs
| Résumé : | The discovery of diseased tissue-specific neoantigens offers the opportunity to develop important disease tissue-specific biomarkers that can help in the prediction, diagnosis, and stratification of diseases. This opportunity is specifically significant for autoimmune diseases where diagnostic biomarkers are not available. Inflammatory autoimmune diseases are commonly associated with local generation of large amounts of reactive oxidants. We have previously identified oxidative post-translationally modified (oxPTM) tissue-specific neoantigens in rheumatoid arthritis (RA) and type 1 diabetes that elicit an immune response. In the current study, we studied the presence and clinical significance of antibodies to oxPTM collagen type II (CII) in patients with spondyloarthritis (SpA). |
